Creoptix - Privilège Ventures SA

COMPANY INFO

MEDTECH – Switzerland

EXIT 2022

COMPANY PROFILE

Creoptix founded in 2009 is based in Wädenswil, Switzerland. The company is specialized in optical instruments and consumables for the label-free analysis of molecular interactions at best-in-class sensitivity for life science research and the drug discovery industry. Creoptix is revolutionizing the study of label-free molecular interactions and changing the world of drug discovery.

NEWS

Malvern Panalytical expands pharmaceutical drug development solutions through the acquisition of Creoptix

greta2023-09-07T09:52:03+01:00January 11th, 2022|

Creoptix launches new way of measuring kinetics to accelerate drug discovery

greta2023-10-12T09:06:36+01:00February 2nd, 2021|

Domainex invests in the Creoptix WAVEdelta to strengthen its fragment-based drug discovery platform

greta2023-10-12T09:05:56+01:00January 12th, 2021|

Swiss start-ups drive research around Covid-19

greta2023-10-12T09:05:10+01:00May 27th, 2020|

Microfluidics mastery earns Switzerland’s Creoptix $8m Series C

greta2023-10-12T09:01:56+01:00October 4th, 2019|

Creoptix raises CHF8m Series C financing round

greta2023-10-12T09:04:24+01:00September 30th, 2019|